David BAKER Professor of Neuroimmunology QMUL London Contact: [email protected] Education Bedford College, University of London BSc (Zoology) Hunterian Institute, University of London PhD (Immunology) 1983 1987 Employment History: QMUL London UCL Institute of Neurology UCL Institute of Neurology UCL Institute of Ophthalmology, Professor 2006-present Professor 2004-2006 Senior Lecturer 1999-2004 Principal Research Fellow/Senior Lecturer 1994-2000 Hunterian Institute London, Lecturer 1988-1994 Institute of Basic Medical Sciences Research Assistant 1983-1988 BIOGRAPHY Following completing a BSc in Zoology in 1983, he performed post-graduate studies at the Royal College of Surgeons of England on immune tolerance and delayed hypersensitivity responses in the skin. These formed the basis for his PhD. Following the award of Angela Limerick Lectureship to study multiple sclerosis, he turned his attention to delayed hypersensitivity responses in the brain. He developed a novel relapsing model of multiple sclerosis in Biozzi Mice in 1989 and has been working with them ever since. Although his interests have varied over time, his focus has been on control of neuroimmunological disease and its translational relevance to multiple sclerosis (MS) and has published over 200 peer-reviewed papers. His early career focused on Genetics; T cell biology and neuroimmunology and blood brain barrier function to name a few examples. In 1994 he became the first ever recipient of a Multiple Sclerosis Society UK Senior fellowship. He moved to the Institute of Ophthalmology to develop ocular models of central nervous system autoimmunity and further develop blood-brain barrier studies to complement the MS work. There his group uncovered the first experimental evidence for symptomatic benefit of cannabis and cannabinoids in the control of spasticity. This work led to the development of cannabis-based licensed medicines for treatment of spasticity in MS. His research has focussed on developing alternatives to cannabis that exploit the endocannabinoid system to treat symptoms and promote neuroprotection. He moved to the Institute of Neurology in 1999 to continue his work on spasticity and there developed a novel anti-spastic drug that lacks the side-effect potential of current anti-spastic compounds. He founded a University spinout company in 2005 to develop his intellectual property and the drug recently completed first in man studies, with plans to enter trials in MS in late 2014. Having become adept at controlling the peripheral immune response, he used this knowledge to 3Rs “refined” EAE models and created secondary progressive MS models to target studies towards neuroprotection. In 2006 he teamed up with Professor Gavin Giovannoni and moved to Queen Mary University of London, to lead the pre-clinical part of a translational neuroscience team. In addition to trials on symptom control, the team have recently translated some neuroprotection studies from animals into human and have developed some novel trial designs to speed the drug development process. The team have also embraced public engagement of science to run a MS research blog (www.ms-res.org). RECENT (SELECTED) PUBLICATIONS Baker D, Amor S. (2010) Quality control of experimental autoimmune encephalomyelitis. Mult Scler. 16:1025-7 Baker D, Gerritsen W, Rundle J, Amor S. (2011) Critical appraisal of animal models of multiple sclerosis. Mult Scler. 17:647-657. Al-Izki, Pryce G, Jackson SJ, Giovannoni G, Baker D. (2011) Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis. J Mullt Scler. 17:939-48. Baker D, Amor S. (2012) Publication guidelines for refereeing and reporting on animal use in experimental autoimmune encephalomyelitis. J Neuroimmunol. 242:78-83 Al-Izki S, Pryce G, O’Neill JK, Butter C, Giovannoni G, Baker D (2012). Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Mult sclera Relat Dis. 1:29-38 M Kipp M, van der Star B, Vogel DYS, Puentes F, van der Valk P, Baker D, Amor S (2012) Experimental in vivo and in vitro Models of Multiple Sclerosis: EAE and beyond. Mult scler Rel Dis. 1:15-28 Baker D, Pryce G, Jackson SJ, Bolton C, Giovannoni G. (2012) The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis. Mult sclera Relat Dis. 1:64-75. Hampton DW, Serio A, Pryce G, Al-Izki S, Franklin RJ, Giovannoni G, Baker D, Chandran S. (2013) Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis. Acta Neuropathol Commun. 1(1):84. Sisay S, Pryce G, Jackson SJ, Tanner C, Ross RA, Michael GJ, Selwood DL, Giovannoni G, Baker D. (2013) Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB 2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosis. PLoS One. 8(10):e76907 Lidster K, Jackson SJ, Ahmed Z, Munro P, Coffey P. Giovannoni G, Baker MD, Baker D. (2013) Neuroprotection in a novel model of multiple sclerosis. PLoS One 8(11): e79188. Puentes F, van der Star BJ, Victor M, Kipp M, Beyer C, Peferon-Baert R, Pryce G, Geritsen W, Huizinga R, Reijerkerk A, van der Valk, P, Baker D, Amor S. (2013) T cell autoimmunity to neurofilament light in EAE. J Neuroflammation. 10(1):118 Al-Izki S, Pryce G, Hankey DJR, Browne L, Clutterbuck L, Posada C, Chan AWE, Amor S, Perkins V, Gerritsen WH, van der Valk P, Montoya A, Ghazaly EA, Joel SP, Garthwaite J, Giovannoni G, Selwood DL, Baker D. (2014) Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis. Brain. 137:92-108. Pryce G, Visintin C, Ramagopalan SV, Al-Izki S, de Faveri LE, Mein CA, Montpetit Hardcastle AJ, Kooij G, de Vries HE, Amor S, Thomas SA, Ledent C, Marsicano G, Lutz B, Thompson AJ, Selwood DL, Giovannon G, Baker D. (2014) Control of Spasticity in experimental multiple sclerosis using central nervous system-excluded CB1 cannabinoid receptor agonists. FASEB J. 28:117-130. Baker D, Lidster K, Sottomayor A, Lidster K, Amor S (2014). Two Years Later: Journals Are Not Yet Enforcing the ARRIVE Guidelines on Reporting Standards for Preclinical Animal Studies PLOSBiol. Jan;12(1):e1001756. Baker D, Amor S (2014). Experimental autoimmune encephalomyelitis is a good model of multiple sclerosis if used wisely. Mult Scler Rel Dis May 2014 [Epub].
© Copyright 2018 ExploreDoc